Evogene Completes Sale of Lavie Bio to ICL Group, Enhancing Global Reach in Sustainable Agriculture
PorAinvest
domingo, 24 de agosto de 2025, 1:41 am ET1 min de lectura
EVGN--
The transaction, which follows ICL's strategic investment and over two years of collaboration with Lavie Bio, aims to accelerate the development of innovative agricultural solutions globally. ICL Group will now have access to Lavie Bio's core team, BDD technology platform, microbial bank, data assets, development programs, and commercial products. The deal excludes Lavie Bio's existing partner agreements, which will continue to generate potential future revenues for Lavie Bio's shareholders.
Evogene's sale of Lavie Bio and MicroBoost AI Tech-Engine for Agriculture to ICL aligns with its goal to unlock subsidiary value while strengthening ICL's position in the global ag-biologicals market. This strategic move allows Evogene to focus on its core competencies, including the development of its ChemPass AI tech-engine for pharmaceutical applications and generating value from other subsidiaries.
The sale is a significant step for Evogene, marking a turning point in its strategic direction. By divesting non-core assets, Evogene can redirect its resources and expertise towards its primary mission of enhancing crop productivity, therapeutic discoveries, and sustainable industrial solutions through cutting-edge computational methods.
References:
[1] https://www.stocktitan.net/news/EVGN/
ICL--
Evogene has completed the sale of its ag-biologicals subsidiary, Lavie Bio, to ICL Group Ltd. The acquisition includes Lavie Bio's technology platform, microbial bank, pipeline, and commercial products, as well as the transfer of core individuals to ICL. Evogene has also sold its MicroBoost AI for AG platform. The transaction is a strategic turning point that will multiply Evogene's global reach and promote sustainable agriculture.
Evogene Ltd. (EVGN), a leader in computational biology, has completed the sale of its ag-biologicals subsidiary, Lavie Bio, to ICL Group Ltd. [1] The acquisition includes Lavie Bio's technology platform, microbial bank, pipeline, and commercial products, as well as the transfer of core individuals to ICL. Additionally, Evogene has sold its MicroBoost AI for AG platform. This strategic move is expected to significantly enhance Evogene's global reach and promote sustainable agriculture.The transaction, which follows ICL's strategic investment and over two years of collaboration with Lavie Bio, aims to accelerate the development of innovative agricultural solutions globally. ICL Group will now have access to Lavie Bio's core team, BDD technology platform, microbial bank, data assets, development programs, and commercial products. The deal excludes Lavie Bio's existing partner agreements, which will continue to generate potential future revenues for Lavie Bio's shareholders.
Evogene's sale of Lavie Bio and MicroBoost AI Tech-Engine for Agriculture to ICL aligns with its goal to unlock subsidiary value while strengthening ICL's position in the global ag-biologicals market. This strategic move allows Evogene to focus on its core competencies, including the development of its ChemPass AI tech-engine for pharmaceutical applications and generating value from other subsidiaries.
The sale is a significant step for Evogene, marking a turning point in its strategic direction. By divesting non-core assets, Evogene can redirect its resources and expertise towards its primary mission of enhancing crop productivity, therapeutic discoveries, and sustainable industrial solutions through cutting-edge computational methods.
References:
[1] https://www.stocktitan.net/news/EVGN/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios